RU98119523A - COMPOUNDS OF PIPERAZIN AND PIPERIDINE - Google Patents

COMPOUNDS OF PIPERAZIN AND PIPERIDINE

Info

Publication number
RU98119523A
RU98119523A RU98119523/04A RU98119523A RU98119523A RU 98119523 A RU98119523 A RU 98119523A RU 98119523/04 A RU98119523/04 A RU 98119523/04A RU 98119523 A RU98119523 A RU 98119523A RU 98119523 A RU98119523 A RU 98119523A
Authority
RU
Russia
Prior art keywords
formula
group
compound
salts
phenyl
Prior art date
Application number
RU98119523/04A
Other languages
Russian (ru)
Other versions
RU2178414C2 (en
Inventor
Рулоф Виллем Фенстра
Корнелис Геррит Крюсе
Мартинус Теодорус Мария Тюлп
Вильма Кейперс
Стивен Кеннет Лонг
Original Assignee
Дюфар Интернэшнл Рисерч Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дюфар Интернэшнл Рисерч Б.В. filed Critical Дюфар Интернэшнл Рисерч Б.В.
Publication of RU98119523A publication Critical patent/RU98119523A/en
Application granted granted Critical
Publication of RU2178414C2 publication Critical patent/RU2178414C2/en

Links

Claims (6)

1. Соединения формулы a
Figure 00000001

в которой A обозначает гетероциклическую группу с 5-7 атомами в кольце, содержащую 1-3 гетероатомами из группы O, N и S; R1 обозначает водород или фтор; R2 обозначает C1-4алкил, C1-4алкокси или оксогруппу, и p равен 0, 1 или 2; Z обозначает углерод или азот, и пунктирная линия обозначает простую связь, когда Z является азотом, и простую или двойную связь, когда Z является углеродом; R3 и R4 независимо друг от друга обозначают водород или C1-4алкил; n равен 1 или 2; R5 обозначает галоген, гидрокси, C1-4алкокси или C1-4алкил, и q равен 0, 1, 2 или 3; Y обозначает фенил, фуранил или тиенил, которые могут быть замещены 1-3 заместителями из группы гидрокси, галоген, C1-4алкокси, C1-4алкил, циано, аминокарбонил, моно- иди ди-C1-4алкиламинокарбонил; и их соли.1. The compounds of formula a
Figure 00000001

in which A denotes a heterocyclic group with 5-7 atoms in the ring, containing 1-3 heteroatoms from the group O, N and S; R 1 denotes hydrogen or fluorine; R 2 is C 1-4 alkyl, C 1-4 alkoxy or oxo, and p is 0, 1 or 2; Z is carbon or nitrogen, and the dotted line indicates a single bond when Z is nitrogen, and a single or double bond when Z is carbon; R 3 and R 4 independently of one another denote hydrogen or C 1-4 alkyl; n is 1 or 2; R 5 is halogen, hydroxy, C 1-4 alkoxy or C 1-4 alkyl, and q is 0, 1, 2 or 3; Y is phenyl, furanyl or thienyl, which may be substituted by 1 to 3 substituents from the group of hydroxy, halogen, C 1-4 alkoxy, C 1-4 alkyl, cyano, aminocarbonyl, mono di di C 1-4 alkylaminocarbonyl; and their salts. 2. Соединения по п.1, отличающиеся тем, что A вместе с фенильной группой является группой формулы b-m. 2. Compounds according to claim 1, characterized in that A together with a phenyl group is a group of the formula b-m.
Figure 00000002

Figure 00000003

Figure 00000004

Figure 00000005

Figure 00000006

Figure 00000007

в которой R1 и (R2)p имеют значения, указанные в п.1, n равен 1, R3, R4, (R5)q, Y и Z имеют значения, указанные в пункте 1, и их соли.
Figure 00000002

Figure 00000003

Figure 00000004

Figure 00000005

Figure 00000006

Figure 00000007

in which R 1 and (R 2 ) p have the meanings indicated in item 1, n is 1, R 3 , R 4 , (R 5 ) q, Y and Z have the meanings indicated in item 1 and their salts. 3. Соединения по п.2, отличающиеся тем, что A вместе с фенильной группой является группой формулы (b), или группой формулы (I), которая замещена в гетерокольце оксогруппой, Y обозначает фенил, который может быть замещен, как указано в п.1, Z обозначает азот, и их соли. 3. Compounds according to claim 2, characterized in that A together with a phenyl group is a group of formula (b), or a group of formula (I) which is substituted in the hetero ring with an oxo group, Y represents phenyl which may be substituted as indicated in .1, Z denotes nitrogen, and their salts. 4. Соединения по п.3, отличающиеся тем, что R3 и R4 обозначают водород, R5 обозначает водород, гидрокси, метокси или галоген, Y имеет значения, указанные в п.3, и их соли.4. Compounds according to claim 3, wherein R 3 and R 4 are hydrogen, R 5 is hydrogen, hydroxy, methoxy or halogen, Y is as defined in claim 3, and their salts. 5. Соединения по п.4, отличающиеся тем, что A вместе с фенильной группой формулы (I), которая замещена в гетерокольце оксогруппой, R5 обозначает водород, Y обозначает фенил, и их соли.5. Compounds according to claim 4, characterized in that A together with the phenyl group of formula (I), which is substituted in the hetero ring by an oxo group, R 5 is hydrogen, Y is phenyl, and their salts. 6. Способ получения соединений, заявленных в п.1, который заключается в том, что a) соединение формулы n
Figure 00000008

подвергают взаимодействию с соединением формулы
Figure 00000009

в которой X является отщепляемой группой; или b) соединение формулы n подвергают взаимодействию с соединением формулы
Figure 00000010

и формальдегидом; или c) соединение формулы n подвергают взаимодействию с соединением формулы
Figure 00000011

с последующим восстановлением кетогруппы; или d) соединение формулы
Figure 00000012

подвергают взаимодействию с соединением Y-Br; или e) соединение формулы
Figure 00000013

подвергают взаимодействию с соединением формулы
B(OH)2-Y
причем символы, используемые в этих формулах, имеют значения, указанные в п.1.6. The method of producing compounds claimed in claim 1, which is that a) a compound of the formula n
Figure 00000008

subjected to interaction with the compound of the formula
Figure 00000009

in which X is a leaving group; or b) a compound of formula n is reacted with a compound of formula
Figure 00000010

and formaldehyde; or c) a compound of formula n is reacted with a compound of formula
Figure 00000011

with the subsequent restoration of ketogroup; or d) a compound of the formula
Figure 00000012

subjected to interaction with the compound Y-Br; or e) a compound of the formula
Figure 00000013

subjected to interaction with the compound of the formula
B (OH) 2 -Y
moreover, the symbols used in these formulas have the meanings indicated in paragraph 1.
RU98119523/04A 1996-03-29 1997-03-20 Derivatives of piperazine and piperidine and method of their synthesis RU2178414C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96200864 1996-03-29
EP96200864.5 1996-03-29

Publications (2)

Publication Number Publication Date
RU98119523A true RU98119523A (en) 2000-10-20
RU2178414C2 RU2178414C2 (en) 2002-01-20

Family

ID=8223832

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98119523/04A RU2178414C2 (en) 1996-03-29 1997-03-20 Derivatives of piperazine and piperidine and method of their synthesis

Country Status (25)

Country Link
US (1) US6225312B1 (en)
EP (1) EP0889889B1 (en)
JP (1) JP3989554B2 (en)
CN (1) CN1100055C (en)
AT (1) ATE340173T1 (en)
AU (1) AU708053B2 (en)
BR (1) BRPI9708389B8 (en)
CA (1) CA2250347C (en)
CZ (1) CZ294413B6 (en)
DE (1) DE69736704T2 (en)
DK (1) DK0889889T3 (en)
ES (1) ES2271967T3 (en)
HU (1) HU227454B1 (en)
IL (1) IL126187A0 (en)
NO (1) NO320970B1 (en)
NZ (1) NZ331860A (en)
PL (1) PL189256B1 (en)
PT (1) PT889889E (en)
RU (1) RU2178414C2 (en)
SK (1) SK285119B6 (en)
TR (1) TR199801942T2 (en)
TW (1) TW422846B (en)
UA (1) UA52656C2 (en)
WO (1) WO1997036893A1 (en)
ZA (1) ZA972639B (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0900792B1 (en) * 1997-09-02 2003-10-29 Duphar International Research B.V Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists
TW530054B (en) * 1997-09-24 2003-05-01 Duphar Int Res New piperazine and piperidine compounds
EP1146045A1 (en) * 1998-06-30 2001-10-17 Eli Lilly And Company Piperidine derivatives having effects on serotonin related systems
CO5080791A1 (en) * 1998-06-30 2001-09-25 Lilly Co Eli PIPERIDINE DERIVATIVES THAT HAVE EFFECTS ON SYSTEMS WITH SEROTONIN
UA71590C2 (en) * 1998-11-13 2004-12-15 Duphar Int Res Piperazine and piperidine derivatives
DE60002583T2 (en) * 1999-07-29 2004-03-25 Eli Lilly And Co., Indianapolis BENZOFURYL PIPERAZINE AS SEROTONIN AGONISTS
ES2203498T3 (en) * 1999-07-29 2004-04-16 Eli Lilly And Company BENZOFURILPIPERAZINAS: SEROTONINE 5-HT2C RECEPTOR AGONISTS.
KR100791799B1 (en) 2000-05-12 2008-01-04 솔베이 파마슈티칼스 비. 브이 Piperazine and piperidine compounds, and preparation thereof
US20030186838A1 (en) * 2000-05-12 2003-10-02 Feenstra Roelof W. Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders
SK286778B6 (en) * 2000-05-12 2009-05-07 Solvay Pharmaceuticals B. V. Piperazine and piperidine compounds, method for their preparation and pharmaceutical compositions comprising the same and their use
AR034206A1 (en) * 2001-02-16 2004-02-04 Solvay Pharm Bv A PROCEDURE FOR THE PREPARATION OF MESILATES OF PIPERAZINE DERIVATIVES AND SUCH MESILATES
EP1408976B3 (en) 2001-07-20 2010-08-25 Psychogenics Inc. Treatment for attention-deficit hyperactivity disorder
MXPA05004758A (en) 2002-11-08 2005-08-02 Hoffmann La Roche Substituted benzoxazinones and uses thereof.
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
ES2232292B1 (en) * 2003-07-30 2006-11-01 Laboratorios Del Dr. Esteve, S.A. SULFONAMIDIC COMPOUNDS DERIVED FROM BENZOXAZINONA, ITS PREPARATION AND USE AS MEDICATIONS.
US7435738B2 (en) 2003-08-18 2008-10-14 Solvay Pharmaceuticals, Inc. Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
AR045362A1 (en) * 2003-08-18 2005-10-26 Solvay Pharm Bv STABLE CRYSTALLINE FORM OF BIFEPRUNOX MESILATE (MONOMETANSULFONATE 7- [4 - ([1,1- BIFENIL] -3- ILMETIL) -1- PIPERAZINIL] - 2- (3H) -BENZOXAZOLONA
AR048112A1 (en) * 2004-03-25 2006-03-29 Solvay Pharm Bv DERIVATIVES OF 1- (2H-1-BENZOPIRAN-2-ON-8-IL) -PIPERAZINE FOR PAIN TREATMENT
AR049478A1 (en) 2004-03-25 2006-08-09 Solvay Pharm Bv A PROCEDURE FOR THE PREPARATION OF 3-AMINO-8- (1-PIPERAZINIL) -2H-1-BENZOPIRAN-2-ONA. SALTS AND HYDRATES AND PHARMACEUTICAL COMPOSITIONS.
US20050215551A1 (en) * 2004-03-25 2005-09-29 Solvay Pharmaceuticals B.V. 1-[2H-1-benzopyran-2-one-8-yl]- piperazine derivatives for the treatment of movement disorders
US7405216B2 (en) 2004-08-18 2008-07-29 Solvay Pharmaceuticals, B.V. Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
US7371769B2 (en) 2004-12-07 2008-05-13 Solvay Pharmaceuticals B.V. Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
US20070072870A2 (en) 2004-12-08 2007-03-29 Solvay Pharmeceuticals B.V. Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition
US7964604B2 (en) 2005-02-18 2011-06-21 Solvay Pharmaceuticals B.V. Bifeprunox mesylate maintenance dose compositions and methods for using the same
US7423040B2 (en) 2005-02-18 2008-09-09 Irene Eijgendaal Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
US7750013B2 (en) 2005-08-22 2010-07-06 Solvay Pharmaceuticals, B.V. N-oxides as prodrugs of piperazine and piperidine derivatives
AR058022A1 (en) * 2005-08-22 2008-01-23 Solvay Pharm Bv DERIVATIVES OF BENZOOXAZOLES, PHARMACEUTICAL COMPOSITIONS AND ITS USE FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS.
KR20080046205A (en) * 2005-08-22 2008-05-26 솔베이 파마슈티칼스 비. 브이 N-oxides as prodrugs of piperazine & piperidine derivatives
US7786126B2 (en) 2006-06-16 2010-08-31 Solvay Pharmaceuticals B.V. Combination preparations comprising SLV308 and a dopamine agonist
US8106056B2 (en) 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
EP2059244A1 (en) 2006-08-31 2009-05-20 Solvay Pharmaceuticals B.V. Titration schedule for bifeprunox for treating schizophrenia and kits for use therein
TW200840566A (en) * 2006-12-22 2008-10-16 Esteve Labor Dr Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments
US20080299217A1 (en) * 2007-06-01 2008-12-04 Protia, Llc Deuterium-enriched bifeprunox
EP2222639A1 (en) * 2007-11-21 2010-09-01 Decode Genetics EHF Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders
JP2011509969A (en) * 2008-01-15 2011-03-31 アボツト・ヘルスケア・プロダクツ・ベー・ブイ Bifeprunox derivatives
JP2011511011A (en) 2008-02-05 2011-04-07 ハーバー バイオサイエンシーズ，インコーポレイテッド Pharmaceutical solid state form
US20110014121A1 (en) * 2008-11-04 2011-01-20 Chemocentryx, Inc. Modulators of cxcr7
JP5785089B2 (en) * 2008-11-04 2015-09-24 ケモセントリックス，インコーポレイティド Regulators of CXCR7
US8853202B2 (en) * 2008-11-04 2014-10-07 Chemocentryx, Inc. Modulators of CXCR7
DK2445502T4 (en) * 2009-06-25 2022-11-28 Alkermes Pharma Ireland Ltd HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS
CA2937222C (en) * 2009-06-25 2019-06-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
WO2011023796A1 (en) 2009-08-31 2011-03-03 Abbott Healthcare Products B.V. Bifeprunox for treating addiction
PL395469A1 (en) 2011-06-29 2013-01-07 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Indolamines derivatives for the treatment of diseases of the central nervous system
MX359651B (en) 2012-11-29 2018-10-05 Chemocentryx Inc Cxcr7 antagonists.
CN109890371A (en) 2016-08-26 2019-06-14 斯瑞尼瓦萨饶·韦帕切杜 Composition and its method
CN112423754A (en) 2018-03-05 2021-02-26 奥克梅斯制药爱尔兰有限公司 Aripiprazole administration strategy
AU2019398198A1 (en) 2018-12-12 2021-07-08 Chemocentryx, Inc. CXCR7 inhibitors for the treatment of cancer
CN114246869A (en) * 2022-01-18 2022-03-29 万宜合药业(海南)有限责任公司 Anti-tumor activity and application of bifeprunox and derivatives thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2263211A1 (en) * 1972-12-23 1974-07-04 Boehringer Sohn Ingelheim NEW ARYLPIPERAZINE AND PROCESS FOR THEIR PRODUCTION
JPS5777676A (en) 1980-10-31 1982-05-15 Otsuka Pharmaceut Co Ltd Carbostyril derivative
DE3586794T2 (en) 1984-12-21 1993-05-27 Duphar Int Res MEDICINAL PRODUCTS WITH PSYCHOTROPER EFFECT.
EP0190472B1 (en) * 1984-12-21 1989-07-12 Duphar International Research B.V New pharmaceutical compositions having anti-psychotic properties
PH22783A (en) 1986-02-27 1988-12-12 Duphar Int Res New aryl-substituted (n-piperidinyl)methyl-and (n-piperazinyl)methylazoles and pharmaceutical compositions containing the same
FR2602771B1 (en) 1986-08-12 1988-11-04 Rhone Poulenc Sante NOVEL BENZYL-4 PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO1990006303A1 (en) * 1988-12-02 1990-06-14 Pfizer Inc. Arylpiperidine derivatives
US5260317A (en) 1990-07-10 1993-11-09 Adir Et Compagnie Piperidine, tetrahydropyridine and pyrrolidine compounds
US5240942A (en) 1990-07-10 1993-08-31 Adir Et Compagnie Piperidine, tetrahydropyridine and pyrrolidine compounds
US5242933A (en) 1990-07-10 1993-09-07 Adir Et Compagnie Piperidine, tetrahydropyridine and pyrrolidine compounds
FR2664592B1 (en) * 1990-07-10 1994-09-02 Adir NOVEL DERIVATIVES OF PIPERIDINE, TETRAHYDROPYRIDINE AND PYRROLIDINE, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
IE914218A1 (en) * 1991-09-11 1993-03-24 Mcneilab Inc Novel 4-arylpiperazines and 4-arylpiperidines
US5569659A (en) 1991-09-11 1996-10-29 Mcneilab, Inc. 4-arylpiperazines and 4-arylpiperidines
US5436246A (en) 1992-09-17 1995-07-25 Merrell Dow Pharmaceuticals Inc. Serotonin receptor agents
DK148392D0 (en) * 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocyclic Compounds
GB9314758D0 (en) 1993-07-16 1993-08-25 Wyeth John & Brother Ltd Heterocyclic derivatives
EP0650964A1 (en) 1993-11-02 1995-05-03 Duphar International Research B.V 1 2H-1-benzopyran-2-one-8-yl -piperazine derivatives

Similar Documents

Publication Publication Date Title
RU98119523A (en) COMPOUNDS OF PIPERAZIN AND PIPERIDINE
RU96119782A (en) DERIVATIVES 7-AMINO-1H-INDOLA
RU98117621A (en) NEW DERIVATIVES OF PIPERASIN AND PIPERIDINE, METHOD FOR PRODUCING THEM, PHARMACEUTICAL COMPOSITION ON THEIR BASIS, METHOD OF TREATMENT, INTERMEDIATE PRODUCT
KR880001597A (en) Alkylenediamine
ATE152445T1 (en) 3,5-DIOXO-(2H,4H)-1,2,4-TRIAZINE AS 5HT1A LIGAND
GB0113233D0 (en) Chemical compounds
ME00108B (en) Derivatives of dioxane-2-alkyl carbamates, preparation method thereof and application of same in therapeutics
RU2002107318A (en) NEW Phenylpiperazines
RU93046499A (en) METHOD FOR INCREASING THE RELATIVE DENSITY OF POLYAMIDS
RU2006137563A (en) METHOD FOR PRODUCING AMINOPHENOL COMPOUNDS
EA200100310A1 (en) OXYGEN CONTAINING HETEROCYCLIC COMPOUNDS
RU2003105902A (en) METHOD FOR PRODUCING PIPERASIN DERIVATED MESILATES
RU99115165A (en) Method of producing thiazole derivatives
YU46699A (en) Improved method for producing thiazolidinediones, and new thiazolidinediones
AR021114A1 (en) PHOTOSTABILIZATION PROCEDURE OF SOLAR FILTERS DERIVED FROM 1,3,5-TRIAZINE
ATE75737T1 (en) INDENOTHIAZOLE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION.
ZA200002207B (en) Substituted pyridine or piperidine compounds, a process for their preparation and pharmaceutical compositions containing them.
ES466887A2 (en) A procedure for the preparation of a substitute phenylamidine. (Machine-translation by Google Translate, not legally binding)
EA200300458A1 (en) NEW CONNECTIONS OF AMINOTRIAZOLONE, METHOD FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
KR850001194A (en) compound
KR850007588A (en) Method for preparing β-naphthylalkylamine
RU2006119924A (en) METHODS FOR PRODUCING HEXAN BICYCLO [3.1.0] DERIVATIVES AND INTERMEDIATE COMPOUNDS FOR THIS PURPOSE
RU99115082A (en) DIPHENYLALKYL-TETRAHYDROPYRIDINES, METHOD FOR THEIR RECEPTION AND PHARMACEUTICAL COMPOSITIONS THEM CONTAINING
RU2007111957A (en) PIPERIDINE DERIVATIVE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT
NZ511092A (en) Heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane compounds and pharmaceutical compositions thereof